{"url":"https://lda.senate.gov/api/v1/filings/666766aa-c0fe-4e18-a2cb-5ea55b8a464d/","filing_uuid":"666766aa-c0fe-4e18-a2cb-5ea55b8a464d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2014,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/666766aa-c0fe-4e18-a2cb-5ea55b8a464d/print/","filing_document_content_type":"text/html","income":"21000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Ellen P. Carlin","dt_posted":"2014-04-16T20:26:11.990000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3430 Connecticut Avenue NW, #4938","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20008","registrant":{"id":401103172,"url":"https://lda.senate.gov/api/v1/registrants/401103172/","house_registrant_id":42470,"name":"CARLIN COMMUNICATIONS","description":"Science policy writing and consulting","address_1":"3430 Connecticut Avenue NW, #4938","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20008","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ELLEN P. CARLIN","contact_telephone":"+1 202-669-7830","dt_updated":"2022-04-06T16:07:43.246442-04:00"},"client":{"id":198070,"url":"https://lda.senate.gov/api/v1/clients/198070/","client_id":12,"name":"BAVARIAN NORDIC A/S","general_description":"Biotechnology","client_government_entity":false,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":null,"ppb_state_display":null,"ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-11-04"},"lobbying_activities":[{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"FY15 appropriations for biodefense aspects of homeland security, specifically BARDA, BioShield, Strategic National Stockpile, and pandemic influenza accounts. General educational meetings on smallpox preparedness.","foreign_entity_issues":"Bavarian Nordic A/S manufactures smallpox vaccine for Strategic National Stockpile.","lobbyists":[{"lobbyist":{"id":59609,"prefix":null,"prefix_display":null,"first_name":"ELLEN","nickname":null,"middle_name":null,"last_name":"CARLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"FY15 appropriations for biodefense, specifically BARDA, BioShield, Strategic National Stockpile, and pandemic influenza accounts. General educational meetings on smallpox preparedness and medical countermeasures.","foreign_entity_issues":"Bavarian Nordic A/S manufactures smallpox vaccine for Strategic National Stockpile.","lobbyists":[{"lobbyist":{"id":59609,"prefix":null,"prefix_display":null,"first_name":"ELLEN","nickname":null,"middle_name":null,"last_name":"CARLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}